First Trust Nasdaq Pharmaceuticals ETF
FTXH
7 hedge funds and large institutions have $1.08M invested in First Trust Nasdaq Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
1,482% more capital invested
Capital invested by funds: $68.2K → $1.08M (+$1.01M)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
40% more funds holding
Funds holding: 5 → 7 (+2)
29.92% more ownership
Funds ownership: 3.25% → 33.17% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$963K |
| 2 |
SMFS
Squar Milner Financial Services
Irvine,
California
|
+$12.6K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$8.51K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $983K | +$963K | +45,294 | New |
|
2
Bank of America
Charlotte,
North Carolina
| $43K | – | – | – |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $21K | +$8.51K | +400 | +72% |
|
|
SMFS
4
Squar Milner Financial Services
Irvine,
California
| $13K | +$12.6K | +590 | New |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $8K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $6K | +$5.66K | +266 | New |
|
|
APA
7
American Portfolios Advisors
Holbrook,
New York
| $5.42K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$1K | -46 | Closed |
|
FTXH Hedge Fund Activity: Q2 2018 in Review
7 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2018, worth a combined $1.08M — up 1,482% from $68.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new FTXH positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $963K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1K sold.
- 7 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2018, up from 5 in Q1 2018.
- Funds reported $1.08M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2018, up 1,482% quarter-over-quarter.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2018 and 1 closed out, a net change of +2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2018 was Jane Street, an estimated $963K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2018 was Tower Research Capital (TRC), an estimated $1K sold.
Based on aggregated 13F filings for Q2 2018.